Unravelling the Inflammatory Code of Alzheimer’s Disease
A recent study in the Bio-Hermes cohort provides a detailed map of plasma inflammatory biomarker profiles across the Alzheimer’s disease spectrum. Researchers analyzed 32 cytokines, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) in 964 participants, ranging from cognitively normal to mild Alzheimer’s disease. The findings reveal distinct, stage-specific inflammatory signatures. A core set of 14 cytokines and NfL were altered independent of amyloid pathology, while a broader, amyloid-specific profile emerged, including GFAP, interleukin-1β, and interleukin-18, pointing to specific activation of microglial inflammasomes and astrocytes. This work highlights the complex, heterogeneous role of innate and adaptive immune responses, including cytokine and chemokine networks, in neurodegeneration.
Study Significance: For immunologists, this research underscores the potential of peripheral immune signatures as non-invasive biomarkers for disease staging and therapeutic targeting in Alzheimer’s. The identification of amyloid-dependent and independent inflammatory pathways clarifies the immune system’s dual role as both a driver and amplifier of pathology, offering new avenues for immunotherapy development. These insights into immune dysregulation and cytokine storm dynamics in a chronic neurological condition can inform broader strategies for modulating inflammation across various immunopathological states.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
